Flunisolide

Features and Benefits This compound was developed by Roche . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here .

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

MF: C3H7NO2 MF: 89.09 CAS: 107-97-1 Purity: >99% by Titration

This pool is delivered in one pool of 53 peptides derived from a peptide scan (15mers with 11 aa overlap) through Spike glycoprotein - Receptor binding domain (mutation: N501Y) of SARS-CoV-2 (Severe Acute Respiratory Syndrome-related coronavirus 2)